These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

370 related articles for article (PubMed ID: 33275677)

  • 1. Updates on the diagnosis and management of the most common hereditary porphyrias: AIP and EPP.
    Linenberger M; Fertrin KY
    Hematology Am Soc Hematol Educ Program; 2020 Dec; 2020(1):400-410. PubMed ID: 33275677
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Congenital erythropoietic porphyria and erythropoietic protoporphyria: Identification of 7 uroporphyrinogen III synthase and 20 ferrochelatase novel mutations.
    Weiss Y; Balwani M; Chen B; Yasuda M; Nazarenko I; Desnick RJ
    Mol Genet Metab; 2019 Nov; 128(3):358-362. PubMed ID: 30454868
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Erythropoietic protoporphyria.
    Lecha M; Puy H; Deybach JC
    Orphanet J Rare Dis; 2009 Sep; 4():19. PubMed ID: 19744342
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cimetidine Does Not Inhibit 5-Aminolevulinic Acid Synthase or Heme Oxygenase Activity: Implications for Treatment of Acute Intermittent Porphyria and Erythropoietic Protoporphyria.
    Yasuda M; Lee S; Gan L; Bergonia HA; Desnick RJ; Phillips JD
    Biomolecules; 2023 Dec; 14(1):. PubMed ID: 38254627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Porphyrias-what is verified?].
    Stölzel U; Kubisch I; Stauch T
    Internist (Berl); 2018 Dec; 59(12):1239-1248. PubMed ID: 30328490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Recent advances on porphyria genetics: Inheritance, penetrance & molecular heterogeneity, including new modifying/causative genes.
    Yasuda M; Chen B; Desnick RJ
    Mol Genet Metab; 2019 Nov; 128(3):320-331. PubMed ID: 30594473
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Erythropoietic Protoporphyria and X-Linked Protoporphyria: pathophysiology, genetics, clinical manifestations, and management.
    Balwani M
    Mol Genet Metab; 2019 Nov; 128(3):298-303. PubMed ID: 30704898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Liver Transplantation for Acute Intermittent Porphyria: Biochemical and Pathologic Studies of the Explanted Liver.
    Yasuda M; Erwin AL; Liu LU; Balwani M; Chen B; Kadirvel S; Gan L; Fiel MI; Gordon RE; Yu C; Clavero S; Arvelakis A; Naik H; Martin LD; Phillips JD; Anderson KE; Sadagoparamanujam VM; Florman SS; Desnick RJ
    Mol Med; 2015 Jun; 21(1):487-95. PubMed ID: 26062020
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Murine models of the human porphyrias: Contributions toward understanding disease pathogenesis and the development of new therapies.
    Yasuda M; Desnick RJ
    Mol Genet Metab; 2019 Nov; 128(3):332-341. PubMed ID: 30737139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Homozygous hydroxymethylbilane synthase knock-in mice provide pathogenic insights into the severe neurological impairments present in human homozygous dominant acute intermittent porphyria.
    Yasuda M; Gan L; Chen B; Yu C; Zhang J; Gama-Sosa MA; Pollak DD; Berger S; Phillips JD; Edelmann W; Desnick RJ
    Hum Mol Genet; 2019 Jun; 28(11):1755-1767. PubMed ID: 30615115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Heme biosynthesis and the porphyrias.
    Phillips JD
    Mol Genet Metab; 2019 Nov; 128(3):164-177. PubMed ID: 31326287
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular characterization of porphyrias in Italy: a diagnostic flow-chart.
    Martinez di Montemuros F; Di Pierro E; Patti E; Tavazzi D; Danielli MG; Biolcati G; Rocchi E; Cappellini MD
    Cell Mol Biol (Noisy-le-grand); 2002 Dec; 48(8):867-76. PubMed ID: 12699245
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Erythropoietic and hepatic porphyrias.
    Gross U; Hoffmann GF; Doss MO
    J Inherit Metab Dis; 2000 Nov; 23(7):641-61. PubMed ID: 11117426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of volatile anaesthetics on heme metabolism in a murine genetic model of Acute Intermittent Porphyria. A comparative study with other porphyrinogenic drugs.
    Ruspini SF; Zuccoli JR; Lavandera JV; Martínez MDC; Oliveri LM; Gerez EN; Batlle AMDC; Buzaleh AM
    Biochim Biophys Acta Gen Subj; 2018 Jun; 1862(6):1296-1305. PubMed ID: 29476795
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pathogenesis and clinical features of the acute hepatic porphyrias (AHPs).
    Bonkovsky HL; Dixon N; Rudnick S
    Mol Genet Metab; 2019 Nov; 128(3):213-218. PubMed ID: 30987916
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Guide and Update on Porphyrias.
    Stölzel U; Doss MO; Schuppan D
    Gastroenterology; 2019 Aug; 157(2):365-381.e4. PubMed ID: 31085196
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Understanding Carbohydrate Metabolism and Insulin Resistance in Acute Intermittent Porphyria.
    Solares I; Jericó D; Córdoba KM; Morales-Conejo M; Ena J; Enríquez de Salamanca R; Fontanellas A
    Int J Mol Sci; 2022 Dec; 24(1):. PubMed ID: 36613492
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acute intermittent porphyria.
    Herrick AL; McColl KE
    Best Pract Res Clin Gastroenterol; 2005 Apr; 19(2):235-49. PubMed ID: 15833690
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 19.